Vascular disrupting agent for neovascular age related macular degeneration: A pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Ibrahim, Mohamed A ^a   Do, Diana V ^a,e   Sepah, Yasir J ^a   Shah, Syed M ^a   Van Anden, Elizabeth ^a   Hafiz, Gulnar ^a   Donahue, J Kevin ^b,c   Rivers, Richard ^b   Balkissoon, Jai ^d   Handa, James T ^a   Campochiaro, Peter A ^a   Nguyen, Quan Dong ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OXiGENE Inc   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; CA4P; Combretastatin A 4 Phosphate; Neovascularization; Ocular pharmacology; Retinal degeneration; Vascular disrupting agents; VDA

Indexed keywords

CA 4P; COMBRETASTATIN A4 PHOSPHATE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; STILBENE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; LABORATORY TEST; MALE; NAUSEA; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHYSICAL EXAMINATION; PILOT STUDY; PROSPECTIVE STUDY; QT PROLONGATION; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; T WAVE INVERSION; TACHYCARDIA; THORAX PAIN; VISUAL ACUITY; VITAL SIGN; CHEMICALLY INDUCED DISORDER; FEVER; HEADACHE; INTRAVENOUS DRUG ADMINISTRATION; LONG QT SYNDROME; MIDDLE AGED; PATHOLOGY; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FEMALE; FEVER; HEADACHE; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MACULAR DEGENERATION; MALE; MIDDLE AGED; PILOT PROJECTS; STILBENES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84879811416     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-7     Document Type: Article

References (19)

1. Hu E, Ko R, Koda R, Rosen P, Jeffers S, Scholtz M, Muggia F. Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemother Pharmacol 1990, 26(5):359-364. 10.1007/BF02897294, 2208579.
2. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005, 11(2 Pt 1):416-420.
3. Duncan DD, Lemaillet P, Ibrahim M, Nguyen QD, Hiller M, Ramella-Roman J. Absolute blood velocity measured with a modified fundus camera. J Biomed Opt 2010, 15(5):056014. 10.1117/1.3494565, 2966492, 21054108.
4. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009, 18(2):189-197. 10.1517/13543780802691068, 19236265.
5. Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 2002, 160(3):1097-1103. 10.1016/S0002-9440(10)64930-9, 1867165, 11891206.
6. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44(8):3650-3655. 10.1167/iovs.02-0985, 12882819.
7. Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, Bhakta S, Lavertu P, Ortiz J, Remick S. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol (Meet Abstracts) 2006, 24(18_suppl):5580.
8. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62(12):3408-3416.
9. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003, 21(23):4428-4438. 10.1200/JCO.2003.12.986, 14645433.
10. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21(15):2815-2822. 10.1200/JCO.2003.05.185, 12807934.
11. Martel CL, Ebrahimi B, Horns RC, Upadhyaya GH, Vakil MJ, Yeon CH, Bosserman LD, Presant CA. Incidence of bevacizumab (BE) related toxicities: Association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS). J Clin Oncol 2005, 23(16):744s.
12. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005, 112(6):1035-1047. 10.1016/j.ophtha.2005.02.007, 15936441.
13. Schmid-Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S. Systemic bevacizumab (avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-study. Br J Ophthalmol 2009, 93(7):914-919. 10.1136/bjo.2008.144410, 19406737.
14. Geitzenauer W, Michels S, Prager F, Rosenfeld PJ, Kornek G, Vormittag L, Schmidt-Erfurth U. Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study. Retina 2008, 28(10):1375-1386. 10.1097/IAE.0b013e3181863f96, 18784625.
15. Spaide RF, Koizumi H, Freund KB. Photoreceptor outer segment abnormalities as a cause of blind spot enlargement in acute zonal occult outer retinopathy-complex diseases. Am J Ophthalmol 2008, 146(1):111-120. 10.1016/j.ajo.2008.02.027, 18439564.
16. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004, 10(1):96-100. 10.1158/1078-0432.CCR-0364-3, 14734457.
17. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001, 2(2):82-87. 10.1016/S1470-2045(00)00224-2, 11905799.
18. Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, Taylor NJ, Stirling JJ, Sinha R, Walicke P, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009, 19(11):2728-2738. 10.1007/s00330-009-1469-4, 19547986.
19. Patterson DMRGJS, Serradell N, Rosa E, Bolos J. Combretastatin A-4 phosphate: Vascular disrupting agent oncolytic treatment of age-related macular degeneration. Drugs future 2007, 32(12):1025-1032.